Save
Do the newly available therapies mitigate the role of surgery in this setting?
ESGO eAcademy, Coleman Robert, 373783
Secondary cytoreductive surgery in recurrent ovarian cancer: Summary of the current trial data (2022)
ESGO eAcademy, Stefano Greggi, 373782
Radiotherapy: overview radiotherapy aspects, management of locally advanced, follow-up
ESGO eAcademy, Remi Nout, 373781
Surgical aspects: diagnosis, management of early stage, reconstructive techniques
ESGO eAcademy, Christina Fotopoulou, 373780
Special aspects regarding vaginal cancer in childhood and adolescence
ESGO eAcademy, Gabriele Calaminus, 373779
New HRD tests on the horizon
ESGO eAcademy, Toon Van Gorp, 373778
Can we detect PARP resistance?
ESGO eAcademy, Anil K. Sood, 373777
Why we need to test for HRD
ESGO eAcademy, Antonio Gonzalez-Martin, 373776
HPV Vaccines: Current State of the Art and Future Prospects
ESGO eAcademy, Murat Gultekin, 373771
Case discussion: the limits of fertility sparing
ESGO eAcademy, Luis Chiva, 373775
What are the definitive contra-indications for fertility-sparing management
ESGO eAcademy, Denis Querleu, 373774
Oncological and obstetrical outcomes of different fertility-sparing approaches
ESGO eAcademy, Philippe Morice, 373773
Self-Sampling
ESGO eAcademy, Andreas M. Kaufmann, 373772
HPV DNA vs. mRNA An Update on HPV Screenings
ESGO eAcademy, Marc Arbyn, 373770
What‘s new in perioperative care—prehabilitation
ESGO eAcademy, David Cibula, 373769
The implementation of ERAS and ESGO perioperative protocols to everyday practise—why and how to do it
ESGO eAcademy, Maja Pakiz, 373768
The scientific work behind perioperative protocols—how to study and publish multidisciplinary oriented care
ESGO eAcademy, Stephanie Schneider, 373767
Oral poster session 4 : ID 276 - 1657 - 1432
ESGO eAcademy, Faculty / Presenters, 373761
Oral poster session 4 : ID 605 - 1551 - 1311
ESGO eAcademy, Faculty / Presenters, 373760
Oral poster session 4 : ID 1492 - 903 - 972
ESGO eAcademy, Faculty / Presenters, 373759
Imaging in cervical cancer
ESGO eAcademy, Faculty / Presenters, 374703
Imaging in endometrial cancer
ESGO eAcademy, Faculty / Presenters, 373744
Imaging in vulvar cancer
ESGO eAcademy, Faculty / Presenters, 373746
Imaging in ovarian cancer
ESGO eAcademy, Ingfrid Haldorsen, 373747
Sentinel node biopsy diminishes de use of adjuvant therapy in women with early cervical cancer in the SUCCOR cohorT
ESGO eAcademy, ENRIQUE CHACON, 373748
The importance of pathological ultrastaging for sentinel lymph node biopsy in cervical cancer, the final outcome of the Sentix study (CEEGOG-CX01; ENGOT-CX2; NCT02494063)
ESGO eAcademy, Roman Kocian, 373749
Fertility-sparing treatment in patients with IB1 cervical cancer - results of the international multicentre retrospective FERTISS study (ENGOT Cx14; CEEGOG Cx-03)
ESGO eAcademy, Jiri Slama, 373752
Unilateral inguinofemoral lymphadenectomy in patients with early-stage vulvar squamous cell carcinoma and a unilateral metastatic sentinel lymph node is safe
ESGO eAcademy, Willemijn van der Kolk, 373750
Paradigm shift in recurrent/ metastatic cervical cancer? What to expect and what to look for? Live Q&A
ESGO eAcademy, Faculty / Presenters, 374815
Conversations and Controversies in First-line Maintenance Therapy for Advanced Ovarian Cancer: Summary of the session
ESGO eAcademy, Philipp Harter, 374431
Transforming the future of advanced ovarian cancer care: What can we look forward to in 2023 and beyond?
ESGO eAcademy, Antonio Gonzalez-Martin, 374430
Addressing unmet needs: How can we overcome current treatment challenges and improve outcomes in advanced ovarian cancer?
ESGO eAcademy, Toon Van Gorp, 374429
PARP inhibitors in the first-line maintenance setting: How can we use the latest data to guide clinical decision-making?
ESGO eAcademy, Philipp Harter, 374428
New approaches at the horizon for 2L+ treatment of r/m CC
ESGO eAcademy, Faculty / Presenters, 373738
Current developments in 2L treatment of r/m CC
ESGO eAcademy, Faculty / Presenters, 373739
Recent and possible future changes in 1L treatment of r/r CC
ESGO eAcademy, Faculty / Presenters, 373736
Vulvar and clitoral reconstruction using bilateral Singapore island perforator flap after anterior vulvectomy
ESGO eAcademy, Martina Angeles, 373728
Total Excision of Infrarenal Vena Cava in a Patient with Recurrent Endometrial Cancer
ESGO eAcademy, Emin Erhan Donmez, 373729
Coloanal anastomosis after exenteration for recurrent cervical cancer
ESGO eAcademy, Luis Chiva, 373730
Minimally invasive inguinal lymph node dissection technique
ESGO eAcademy, Hisham Abdel Mageed, 373731
Recurrent Cervical Cancer Case With Sacral Metastasis
ESGO eAcademy, Emin Erhan Donmez, 373732
Synthesizing the Data: Moving forward!
ESGO eAcademy, David Cibula, 373733
MIS in Early Cervical Cancer: Still Oncologically Safe
ESGO eAcademy, Henrik Falconer, 373734
MIS in Early Cervical Cancer: No longer a standard
ESGO eAcademy, Pedro Ramirez, 373735
Quality indicators for uterovaginal brachytherapy
ESGO eAcademy, Remi Nout, 373722
What is a high quality external beam radiotherapy for cervical cancer?
ESGO eAcademy, Cyrus Chargari, 373723
Overview of the new quality indicators for cervical cancer management
ESGO eAcademy, Christina Fotopoulou, 373724
PARP after PARP: what have we learned from the OREO/ENGOT-OV38 study
ESGO eAcademy, Antonio Gonzalez-Martin, 373725
Rechallenge of bevacizumab: current evidence and potential clinical opportunities
ESGO eAcademy, Jean-Emmanuel Kurtz, 373726
Surgery in relapsed ovarian cancer: whom, who, when, and how
ESGO eAcademy, Florian Heitz, 373727
A predictive model for detection of epithelial ovarian cancer based on methylation landscape
ESGO eAcademy, Douglas VNP Oliveira, 373715
Pazopanib with Topotecan weekly for patients with platinum-resistant or intermediate-sensitive recurrent ovarian cancer- results of a multicentre NOGGO phase I and II study (TOPAZ)
ESGO eAcademy, Radoslav Chekerov, 373716
Agressive angiomyxoma of the pelvis and vagina: a robotic and vaginal combined approach
ESGO eAcademy, Ana Luzarraga, 373717
Laparoscopic cytoreducion for relapsed gynaecological cancer
ESGO eAcademy, Ignacio Zapardiel, 373718
Total resection of aggressive pelvic angiomyxoma by combination of robotic & vaginal approach.
ESGO eAcademy, Sergi Fernandez, 373719
The case of laparoscopic anterior rectal resection and retransplantaion of theureter with the use of ICG.
ESGO eAcademy, EWA MILNEROWICZ-NABZDYK, 373720
Rectovaginal fistula repair by Martius flap after exclusive chemo-radiation in advanced cervical cancer patient. A case report
ESGO eAcademy, Vito andrea Capozzi, 373721
Intermediate-risk endometrial cancer: isolated tumor cells (ITC) versus node-negative in sentinel lymph node mapping. An international multi-institutional comparative study
ESGO eAcademy, Giuseppe Cucinella, 373714
Identifying women with early-stage cervical cancer at low risk of lymph node metastases, in a large international cohort - A logistic regression analysis, without sharing privacy-sensitive patient data
ESGO eAcademy, Hans Wenzel, 373713
The role of molecular classification in endometrial cancers with lymph nodes metastasis.
ESGO eAcademy, Gabriella Schivardi, 373712
BACK TO THE FUTURE: the impact of estrogen receptor profile in the era of molecular endometrial cancer classification
ESGO eAcademy, Emanuele Perrone, 373711
Role of radiotherapy in platinum sensitive oligometastatic recurrent ovarian cancer: a valid alternative to delay systemic treatment
ESGO eAcademy, Giulio Bonaldo, 373709
Symptomatic or asymptomatic recurrence of ovarian cancer: Does it influence survival?
ESGO eAcademy, Karen Madland, 373708
The significance of lower uterine segment involvement in endometrial cancer
ESGO eAcademy, Sharon Davidesko, 373707
The MULTISENT study: Analysis of survival according to the volume of sentinel lymph node disease
ESGO eAcademy, Silvia Cabrera, 373704
Pattern of recurrence and CA125 monitoring in BRCA wild-typerecurrent ovarian cancer patients under maintenance with Niraparib
ESGO eAcademy, Serena Maria Boccia, 373703
Comparison of PD-L1 status between primary and paired recurrent/metastatic cervical cancer
ESGO eAcademy, Beyhan Ataseven, 374704
Medical options in different ovarian cancer populations
ESGO eAcademy, Jonathan Ledermann, 373701
Pathology and molecular biology
ESGO eAcademy, Xavier Matias-Guiu, 373700
HRD-positive ovarian cancer: PARP inhibitors, bevacizumab - how to choose maintenance therapy in practice
ESGO eAcademy, Isabelle Ray-Coquard, 373699
HRD-negative ovarian cancer: how to choose maintenance therapy in practice and future options
ESGO eAcademy, Antonio Gonzalez-Martin, 373698
BRCA mutated ovarian cancer: PARP inhibitors, bevacizumab- how to choose maintenance therapy in practice
ESGO eAcademy, Banerjee Susana, 373697
Surgical aspects for early, advanced stage and recurrent disease
ESGO eAcademy, Fagotti Anna, 373702
New Era of Immune Checkpoint Inhibitors in Endometrial Cancer: Q&A
ESGO eAcademy, Faculty / Presenters, 374425
The Future of ICI – PD-1/L1 Inhibitors in First-line Treatment of Endometrial Cancer
ESGO eAcademy, Mansoor Raza Mirza, 374424
Diagnosis and Treatment of Advanced EC: Patient Case Study
ESGO eAcademy, Christian Marth, 374423
Treatment of Recurrent EC with ICI: Patient Case Study
ESGO eAcademy, Lucy Gilbert, 374422
Where do Immune Checkpoint Inhibitors Fit in the Patient Journey?
ESGO eAcademy, Jalid Sehouli, 374421
The development of immunotherapy in gestational trophoblastic tumours
ESGO eAcademy, Benoit You, 373696
Management of Gestational Trophoblastic Tumours: Discussion about an illustrative patient case
ESGO eAcademy, Christian Marth, 373695
Role of chemotherapy and identification of new biological targets for drug development in gestational trophoblastic disease
ESGO eAcademy, Gloria Marquina, 373694
Pembrolizumab Monotherapy for Advanced Clear Cell Gynaecological Cancer: Phase II PEACOCC Trial
ESGO eAcademy, Rowan Miller, 373691
Benefit of adjuvant radiotherapy depends on molecular class of early-stage endometrial cancer
ESGO eAcademy, Nanda Horeweg, 373690
The impact of histology, prior therapy, and dMMR status on lenvatinib + pembrolizumab outcomes in patients with advanced endometrial cancer: A subgroup analysis of Study 309/KEYNOTE-775
ESGO eAcademy, Domenica Lorusso, 373689
Discussant
ESGO eAcademy, Toon Van Gorp, 373688
Comparison of the effect of levonorgestrel-intrauterine system with or without oral megestrol acetate on fertility-preserving treatment in patients with atypical endometrial hyperplasia: a prospective, open-label, randomized controlled phase
ESGO eAcademy, Zhiying Xu, 373687
Helga Salvesen Award for Best Translational Research: Introduction and announcement of the award
ESGO eAcademy, Mansoor Raza Mirza, 373686
ENGOT, ENYGO & ENGAGe Anniversary talk
ESGO eAcademy, Mansoor Raza Mirza, 373685
ESGO Presidential talk on ESGO 2022
ESGO eAcademy, Nicole Concin, 373684
Decoding Chaos - analysing the genome of ovarian high grade serous carcinoma
ESGO eAcademy, Iain McNeish, 373683
Major achievements in the management of ovarian cancer (SOLO1, PAOLA1, PRIMA, ATHENAmono, Atalante)
ESGO eAcademy, Mansoor Raza Mirza, 373679
Pro laparoscopic surgery, a conventional method with innovative possibilities
ESGO eAcademy, Mustafa Zelal Muallem, 373680
Pro robotics surgery, new options and indications
ESGO eAcademy, Henrik Falconer, 373681
Advances in endometrial & cervical cancers (ENGOT-EN6, KN775, KN826, EMPOWER, ENGOT-CX6)
ESGO eAcademy, Nicoletta Colombo, 373678
Introduction and announcement of competition
ESGO eAcademy, Fagotti Anna, 373682
Histopathology and staging of the disease
ESGO eAcademy, Alexandros Rodolakis, 373677
New ESGO-ESHRE-ESGE Guidelines on Fertility Sparing in Endometrial Cancer: Medical treatment
ESGO eAcademy, Giovanni Scambia, 373675
Oral posters session 2 : ID 648 - 999 - 922
ESGO eAcademy, Faculty / Presenters, 373668
Clinical relevance of clinicopathological and molecular factors in women with surgically treated stage IV endometrial cancer
ESGO eAcademy, Linda Nooij, 373663
Oral posters session 2 : ID 781 - 1569 - 568
ESGO eAcademy, Faculty / Presenters, 373662

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.



{$cookies-google-tag-manager-description}


Save Settings